专利检索 ap:("The United States of America, as represented by the Secretary, Department of Health AND Human Services") AND inv:"SWAROOP, Anand" 第 1 页

1.

发明公开
? ? ?CRX-? ? ? ? ?GENE THERAPY FOR TREATMENT OFAUTOSOMAL DOMINANT RETINOPATHIES 审中-公开

公开(公告)号：EP4090381A1

公开(公告)日：2022-11-23

申请号：EP21705324.8

申请日：2021-01-15

申请人： The United States of America, as represented by the Secretary, Department of Health and Human Services

发明人： SWAROOP, Anand , WU, Zhijian , HIRIYANNA, Suja D. , KRUCZEK, Kamil

IPC分类号： A61K48/00 , C12N15/864 , C12N15/11 , C12N15/85 , C07K14/47 , A61P27/02

2.

发明公开
CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION 审中-公开

公开(公告)号：EP4175636A2

公开(公告)日：2023-05-10

申请号：EP21751672.3

申请日：2021-07-01

申请人： The United States of America, as represented by the Secretary, Department of Health and Human Services

发明人： HUANG, Wenwei , MONDAL, Anupam , ZHENG, Wei , CHEN, Yu Holly , SWAROOP, Anand , SWAROOP, Manju , TAWA, Gregory , PAPAL, Samantha , LUO, Zhiji

IPC分类号： A61K31/473 , A61K31/475 , A61K31/498 , A61P27/02 , A61K31/137

3.

发明授权
RPGR VECTORS FOR TREATING X-LINKED RETINITIS PIGMENTOSA 有权

公开(公告)号：EP3268481B1

公开(公告)日：2020-05-27

申请号：EP16762623.3

申请日：2016-03-11

申请人： The United States of America, as represented by The Secretary, Department of Health and Human Services

发明人： WU, Zhijian , SWAROOP, Anand , HIRIYANNA, Suja , LI, Tiansen

IPC分类号： C12N15/864 , C12N7/01 , A61P27/02 , A61K48/00

4.

发明公开
RP2 AND RPGR VECTORS FOR TREATING X-LINKED RETINITIS PIGMENTOSA 审中-公开
标题翻译： RP2和RPGR载体用于治疗X-连接的视网膜色素变性

公开(公告)号：EP3268481A1

公开(公告)日：2018-01-17

申请号：EP16762623.3

申请日：2016-03-11

申请人： The United States of America, as represented by the secretary, Department of Health and Human Services

发明人： WU, Zhijian , SWAROOP, Anand , MOOKHERJEE, Suddhasil , HIRIYANNA, Suja , LI, Tiansen

IPC分类号： C12N15/864 , C12N7/01 , A61P27/02 , A61K48/00

摘要： Disclosed are adeno-associated virus (AAV) vectors comprising a nucleotide sequence encoding RP2 or RPGR-ORF15 and related pharmaceutical compositions. Also disclosed are methods of treating or preventing X-linked retinitis pigmentosa, increasing photoreceptor number in a retina of a mammal, and increasing visual acuity of a mammal using the vectors and pharmaceutical compositions.